2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
146 hedge funds and large institutions have $215M invested in 2seventy bio in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 52 increasing their positions, 28 reducing their positions, and 28 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 28
2% less funds holding
Funds holding: 149 → 146 (-3)
11% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 28
48% less call options, than puts
Call options by funds: $50K | Put options by funds: $96K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less capital invested
Capital invested by funds: $505M → $215M (-$290M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$15.3M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$9.8M |
| 3 |
EP
Eversept Partners
New York
|
+$9.53M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$6.97M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$13.1M |
| 4 |
Goldman Sachs
New York
|
-$5.82M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.68M |
TSVT Hedge Fund Activity: Q3 2023 in Review
146 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q3 2023, worth a combined $215M — down 57% from $505M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of TSVT and 25 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 52 added.
The largest buyer was Newtyn Management, adding an estimated $15.3M. The largest seller was OrbiMed, exiting entirely with an estimated $24.2M sold.
- 146 institutional investors held 2seventy bio (TSVT) as of Q3 2023, down from 149 in Q2 2023.
- Funds reported $215M of 2seventy bio stock for Q3 2023, down 57% quarter-over-quarter.
- 25 funds opened new 2seventy bio positions in Q3 2023 and 28 closed out, a net change of -3 holders.
- The largest 2seventy bio buyer in Q3 2023 was Newtyn Management, an estimated $15.3M added.
- The largest 2seventy bio seller in Q3 2023 was OrbiMed, an estimated $24.2M sold.
Based on aggregated 13F filings for Q3 2023.